Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy

BACKGROUND: Daratumumab-based combination therapies have shown high rates of complete response (CR) and minimal residual disease negativity in patients with multiple myeloma. However, daratumumab, an IgGκ monoclonal antibody, interferes with electrophoretic techniques making it difficult to reliably...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Chim Acta
Main Authors: Eveillard, Marion, Korde, Neha, Ciardiello, Amanda, Diamond, Benjamin, Lesokhin, Alexander, Mailankody, Sham, Smith, Eric, Hassoun, Hani, Hultcrantz, Malin, Shah, Urvi, Lu, Sydney, Salcedo, Meghan, Werner, Kelly, Rispoli, Jenna, Mastey, Donna, Landgren, Ola, Thoren, Katie
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7994191/
https://ncbi.nlm.nih.gov/pubmed/33545108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cca.2021.01.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados